Business Headlines: Harvard’s Innovation Lab; More Foreign Students

By Lisa van der Pool, Boston Business Journal
View Comments
Harvard's Innovation Lab (Photo courtesy: Kyle Alspach, Boston Business Journal)

Harvard’s Innovation Lab (Photo courtesy: Kyle Alspach, Boston Business Journal)

BOSTON (CBS) – Genzyme has announced positive results from a phase three study for a potential treatment for multiple sclerosis.

The drug would be marketed as Lemtrada if it gets FDA approval.

Sanofi, Genzyme’s parent company, plans to submit the drug to the FDA and European regulators in the first quarter of next year.


Harvard University is stepping up its efforts to innovate.

The new Innovation Lab in Allston is already hosting events, even though it’s not technically open yet.

It’s a 30,000 square foot facility that Harvard hopes can bring consumer-based tech businesses to Boston.

It could be a game changer for the university as a whole.

Harvard’s focus is mainly on the liberal arts, but this could position Harvard to compete with MIT in terms of high-tech innovation.


And there’s another change on local college campuses.

Massachusetts colleges have seen their enrollment by foreign students jump 9.6 percent this year.

That’s a much bigger increase than the national average, according to the Institute of International Education.

Nearly 39,000 students were studying in Massachusetts during the last academic year.

And that’s part of a nationwide trend.

The number of foreign students studying in the United States is at a record high.

Watch Lisa’s report:

Lisa van der Pool of the Boston Business Journal can be seen weekdays at 6 a.m. on WBZ-TV.

View Comments
blog comments powered by Disqus